


Blood Cancer Awareness Month at King's Health Partners

As an Academic Health Sciences Centre we bring together world-class research, education and clinical practice to improve the lives of patients.

King's Health Partners Haematology Institute

We're combining our strength in haematology across our partners Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts and King's College London to develop treatments and cures for blood cancer and blood disorders.



King's Health Partners includes two of the largest blood cancer centres in the UK.



108,000 blood components are transferred each year across our partnership.



We have one of the largest adult stem cell transplantation programmes in the UK.

BLOOD CANCER: DID YOU KNOW?

104

people are diagnosed with a blood cancer every day in the UK.

£20bn

is the estimated economic burden of blood disorders in the EU.

HOW ARE WE IMPROVING BLOOD CANCER CARE?

Improving diagnosis




We've launched an Adult Haematology GP Referral Guide to help GPs identify potentially serious or urgent blood disorders so patients can get treatment faster.

Supporting learning

Our 'Haematology Case of the Week' learning resource attracts a local, national, and international audience, with more than 50 cases available to review.




Personalised Medicine




We're innovating and developing new approaches to curing people with blood cancer using stem cell therapy.

Caring for mind and body

We're the first in the country to offer integrated physical and mental healthcare to people living with blood cancer.



SUCCESS IN PATIENT TRIALS



We're top recruiters to clinical trials exploring new drugs to treat blood cancers. Our Haematology Trial team recently became a top global recruiter to a clinical trial investigating the use of an experimental drug to treat Myelodysplastic Syndromes, a group of blood cancers that cause a drop in healthy blood cells.

INNOVATION IN CLINICAL RESEARCH



We're pioneering the use of chimeric antigen receptor (CAR) T cell therapies where genetically modified immune cells, called human T cells, are used effectively to kill cancer cells. Early results from trials has shown success against even the most aggressive forms of blood cancers.